However, patients with ovarian cancer have a much higher risk for relapse, and longer PARP inhibitor use could result in a higher rate of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). This evidence concerns the gene PARP1 and ovarian carcinoma.